| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| Cash and cash equivalents | 4,791,676 | 4,547,530 | 4,036,868 | |
| Accounts receivable, net | 938,019 | 865,080 | 863,281 | |
| Inventories, net | 681,590 | 608,227 | 531,687 | |
| Prepaid expenses and other current assets | 189,995 | 212,752 | 232,641 | |
| Total current assets | 6,601,280 | 6,233,589 | 5,664,477 | |
| Land | NaN | 71,434 | NaN | |
| Building | NaN | 1,187,836 | NaN | |
| Machinery And Equipment | NaN | 273,769 | NaN | |
| Laboratory Equipment | NaN | 309,471 | NaN | |
| Software And Software Development Costs | NaN | 124,136 | NaN | |
| Leasehold Improvements | NaN | 76,568 | NaN | |
| Property and equipment, at cost | NaN | 2,043,214 | NaN | |
| Less accumulated depreciation | NaN | 528,695 | NaN | |
| Construction in progress | NaN | 127,159 | NaN | |
| Property, plant and equipment, net | 1,640,918 | 1,641,678 | 1,628,114 | |
| Operating lease right-of-use assets | 145,497 | 148,184 | 140,217 | |
| 2026 (remainder of year) | 6,045 | NaN | 2,090 | |
| 2027-Cost Of Sales | 7,994 | NaN | 8,272 | |
| 2027-Selling General And Administrative Expenses | 67 | NaN | 67 | |
| 2027 | 8,061 | 6,293 | 8,339 | |
| 2027-Cost Of Sales | NaN | 6,226 | NaN | |
| 2027-Selling General And Administrative Expenses | NaN | 67 | NaN | |
| 2028 | 8,061 | 6,293 | 8,339 | |
| 2028 | NaN | 6,293 | NaN | |
| 2030 | 8,061 | 6,293 | 8,339 | |
| 2031 and thereafter | 23,392 | 31,239 | 28,135 | |
| Intangible assets, net | 61,681 | 62,704 | 63,581 | |
| Other non-current assets | 104,243 | 102,418 | 136,197 | |
| Total non-current assets | 1,952,339 | 1,954,984 | 1,968,109 | |
| Total assets | 8,553,619 | 8,188,573 | 7,632,586 | |
| Accounts payable | 423,546 | 479,035 | 383,676 | |
| Accrued expenses and other payables | 1,079,283 | 1,109,120 | 1,001,661 | |
| Tax payable | 63,522 | 41,625 | 11,219 | |
| Operating lease liabilities, current portion | 20,584 | 20,698 | 15,732 | |
| Research and development cost share liability, current portion | 35,700 | 64,345 | 90,596 | |
| Sale of future royalty liability, current portion | 72,735 | 56,714 | 52,245 | |
| Short-term debt | 116,140 | 57,293 | 813,296 | |
| Total current liabilities | 1,811,510 | 1,828,830 | 2,368,425 | |
| Long-term debt | 962,515 | 961,913 | 139,571 | |
| Sale of future royalty liability, non-current portion | 831,664 | 850,242 | 832,755 | |
| Operating lease liabilities, non-current portion | 49,670 | 52,940 | 51,387 | |
| Deferred tax liabilities | 55,866 | 53,209 | 47,066 | |
| Research and development cost share liability, non-current portion | NaN | 0 | 0 | |
| Other long-term liabilities | 81,952 | 80,245 | 64,056 | |
| Total non-current liabilities | 1,981,667 | 1,998,549 | 1,134,835 | |
| Total liabilities | 3,793,177 | 3,827,379 | 3,503,260 | |
| Ordinary shares, 0.0001 par value per share 1,540,975,898 and 1,540,975,898 shares issued and 1,444,479,378 and 1,441,075,618 shares outstanding as of march 31, 2026 and december 31, 2025, respectively | 144 | 144 | 144 | |
| Additional paid-in capital | 12,906,326 | 12,759,137 | 12,616,844 | |
| Accumulated other comprehensive loss | -53,482 | -78,184 | -101,257 | |
| Accumulated deficit | -8,092,546 | -8,319,903 | -8,386,405 | |
| Total shareholders equity | 4,760,442 | 4,361,194 | 4,129,326 | |
| Total liabilities and shareholders equity | 8,553,619 | 8,188,573 | 7,632,586 | |
BeOne Medicines Ltd. (ONC)
BeOne Medicines Ltd. (ONC)